Phio Pharmaceuticals (PHIO) Payables (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Payables came in at $260000.0 in Q1 2026, down 39.11% YoY from $427000.0 in Q1 2025, and down 40.23% on a QoQ basis from $435000.0 in Q4 2025.
Phio Pharmaceuticals (PHIO) Payables (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Payables data on file, last reported at $260000.0 in Q1 2026.
- Quarterly Payables fell 39.11% year-over-year to $260000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $260000.0 (down 39.11% YoY) and the FY2025 annual result came in at $435000.0, up 71.94% from the prior year.
- Payables fell to $260000.0 in Q1 2026, from $435000.0 in the prior quarter.
- In the past five years, Payables ranged from a high of $1.1 million in Q2 2022 to a low of $173000.0 in Q3 2023.
- A 5-year average of $478647.1 and a median of $427000.0 in 2025 frame the typical range for Payables.
- Annual changes were most pronounced in 2022 — Payables surged 229.89% — and 2023, when it plunged 68.14%.
- Tracing PHIO's Payables over 5 years: stood at $779000.0 in 2022, then slipped by 15.66% to $657000.0 in 2023, then slumped by 61.49% to $253000.0 in 2024, then jumped by 71.94% to $435000.0 in 2025, then sank by 40.23% to $260000.0 in 2026.
- The last three Payables figures came in at $260000.0 (Q1 2026), $435000.0 (Q4 2025), and $516000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 35.57 Mn |
| 10 | Phio Pharmaceuticals | 14.00 Mn | 14.00 Mn | - | 901,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 901,000.00 |
| Mar 31, 2026 | 260,000.00 |
| Dec 31, 2025 | 435,000.00 |
| Sep 30, 2025 | 516,000.00 |
| Jun 30, 2025 | 235,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Dec 31, 2024 | 253,000.00 |
| Sep 30, 2024 | 184,000.00 |
| Jun 30, 2024 | 335,000.00 |
| Mar 31, 2024 | 320,000.00 |
| Dec 31, 2023 | 657,000.00 |
| Sep 30, 2023 | 173,000.00 |
| Jun 30, 2023 | 641,000.00 |
| Mar 31, 2023 | 902,000.00 |
| Dec 31, 2022 | 779,000.00 |
| Sep 30, 2022 | 543,000.00 |
| Jun 30, 2022 | 1.15 Mn |
| Mar 31, 2022 | 329,000.00 |
| Dec 31, 2021 | 283,000.00 |
| Sep 30, 2021 | 322,000.00 |